Anicteric Hepatitis in Korea

Chung, Whan-Kook; Moon, Sae-Kuang; Gershon, Richard K.; Prince, Alfred M.; Pópper, Hans

doi:10.1001/archinte.1964.00280100043008

Cited by 28 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Baruch Blumberg and Harvey Alter discovered HBsAg in 1963 [5], and Chung et al independently identified this antigen [6]. Subsequent reports implicated HBsAg in the development of viral hepatitis [31, 32].…”

mentioning

confidence: 99%

“…Before 1970, several studies observed that patients with “serum hepatitis” had detectable levels of “Australia antigen” or “serum hepatitis” [5–7], now known as HBV surface antigen (HBsAg) (Figure 1). Baruch Blumberg and Harvey Alter discovered HBsAg in 1963 [5], and Chung et al independently identified this antigen [6]. Subsequent reports implicated HBsAg in the development of viral hepatitis [31, 32].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention

Koshiol

Liu

O’Brien

et al. 2018

Cancer Epidemiology

View full text Add to dashboard Cite

The 1981 Lancet paper by Beasley et al., "Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan" is a seminal publication that clearly demonstrated that chronic infection with hepatitis B virus (HBV), as measured by seropositivity for the hepatitis B surface antigen (HBsAg), preceded the development of hepatocellular carcinoma (HCC). In doing so, this study paved the way for liver cancer prevention efforts through the implementation of hepatitis B vaccination programs. In this commentary, we will describe the discovery of HBV, which led to the study by Beasley et al.; summarize the major findings of the Beasley paper and its implications; discuss the importance of well-designed cohort studies for prevention activities; and consider the ramifications of the Beasley study and the work that has followed since.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention

Koshiol

Liu

O’Brien

et al. 2018

Cancer Epidemiology

View full text Add to dashboard Cite

show abstract

Anicteric Hepatitis in Korea

Chung¹

1964

Arch Intern Med

View full text Add to dashboard Cite

Current treatment of hepatitis B virus infections

Clercq

2015

Reviews in Medical Virology

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection remains an important global burden with an estimated 240 million HBV carriers worldwide and more than half a million people dying annually from the consequences of the HBV infection. Besides interferon and pegylated interferon, there are five antiviral drugs [lamivudine, adefovir (dipivoxil), entecavir, telbivudine, and tenofovir disoproxil fumarate] that have proved effective in the treatment of chronic hepatitis B. These five antiviral drugs interfere with viral DNA synthesis, which consists of a step reminiscent of the reverse transcriptase step in the replicative cycle of HIV. None of the antiviral drugs, or interferon, are capable of eradicating the covalently closed circular DNA, which remains settled as an episome within the virus-infected hepatocytes. In the short-term (1-3 years), the use of antiviral treatment is aimed at reducing viral DNA below levels of detection, whereas in the long term (10 years and, possibly, lifelong), treatment is aimed at reducing the progression to cirrhosis, hepatocellular carcinoma, liver decompensation, and death. As long as the virus can hide as the episomal covalently closed circular DNA, attempts to envisage a definite cure of the HBV infection may seem fortuitous.

show abstract

Anicteric Hepatitis in Korea

Cited by 28 publications

References 9 publications

Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention

Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention

Anicteric Hepatitis in Korea

Current treatment of hepatitis B virus infections

Contact Info

Product

Resources

About